Developing Targeted Lipid Nanoparticles (tLNPs) to Enable Off-the-Shelf Immunotherapies

Time: 9:10 am
day: Day One


  • Transforming immunotherapy by enabling the reprogramming of immune cells in vivo
  • Designing tLNPs for targeted delivery for oncology, fibrosis and inflammation-related diseases
  • Tight control of dosage and of activity of engineered cells to achieve an advanced, first-in-class therapeutic